Everest Group (EG) came out with quarterly earnings of $6.45 per share, missing the Zacks Consensus Estimate of $7.46 per share. This compares to earnings of $16.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.54%. A quarter ago, it was expected that this reinsurance company would post a loss of $16.65 per share when it actually produced a loss of $18.39, delivering a surprise of -10.45%.Over the last four quarters, the ...

NEWS RELEASE EVEREST GROUP, LTD. Seon place, 141 Front Street, 4 Floor, Hamilton HM 19, Bermuda th Contacts Media: Dawn Lauer Investors: Matt Rohrmann Chief Communications Officer Head of Investor Relations 908.300.7670 908.604.7343 1 • Net Income of $210 million; Net Operating Income of $276 million • Total Shareholder Return of 5.6% annualized ; Annualized year-to-date 5.7% Net Income ROE and 7.5% Net Operating Income ROE 1 • $4.4 billion in gross written premium with year-over-year decreases of 2.0% for ...

Everest Group, Ltd. (EG) is expected to register an improvement in its top line but a decline in its bottom line when it reports first-quarter 2025 results on April 30, after the closing bell.The Zacks Consensus Estimate for EG’s first-quarter revenues is pegged at $4.47 billion, indicating 8.1% growth from the year-ago reported figure.The consensus estimate for earnings is pegged at $7.22 per share. The Zacks Consensus Estimate for EG’s first-quarter earnings has moved down 1.7% in the past 30 days. The es ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Everest Group (EG) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 30. On t ...

Shares of Everest Group, Ltd. (EG) have lost 4.8% in the past year, underperforming the industry and the Zacks S&P 500 composite’s decline of 1% and 3.7%, respectively. The Finance sector has returned 4.5% in the said time frame.  The insurer has a market capitalization of $14.95 billion. The average volume of shares traded in the last three months was 0.4 million. The insurer has a solid track record of beating earnings estimates in three two of the last four quarters while missing in the other two, the av ...

Core Insights - Everest Group recognized Teleperformance (TP) as a Leader in its Experience-Driven Integrated BFS Operations PEAK Matrix® Assessment, highlighting TP's expertise in banking and financial services, technology, and customer-centric approach [1][2] Group 1: Company Recognition and Offerings - TP's OneOffice offering delivers integrated front-to-back operations across lending, payments, and financial crime segments, addressing the demand for end-to-end services [2] - TP's in-house technology and digital services expertise, bolstered by the acquisition of Majorel, enhance its capabilities in digitally driven operations [2] - TP's extensive operational scale and technology, including its digital services arm TP Infinity, contribute to its recognition as a Leader [2][3] Group 2: Strategic Focus and Innovation - TP excels in AI-driven transformation, continuous investment in advanced technologies, and a flexible global delivery model that supports diverse BFS clients [3] - The company has established strong strategic partnerships with AI technology providers, enhancing its service offerings [2][3] Group 3: Financial Performance - In 2023, Teleperformance reported consolidated revenue of €8,345 million (approximately US$9 billion) and a net profit of €602 million [5]

Core Viewpoint - Everest Medicines has initiated the first patient dosing of its personalized mRNA cancer vaccine EVM16 in a clinical trial, marking a significant milestone in its development and potential therapeutic applications for cancer patients [1][5][6]. Group 1: EVM16 Development and Clinical Trials - EVM16 is a personalized mRNA cancer vaccine developed by Everest, designed to target tumor-specific mutations using the proprietary AI-based neoantigen prediction algorithm, EVER-NEO-1 [2][9]. - The clinical trial EVM16CX01 is a first-in-human study aimed at evaluating the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with a PD-1 antibody for patients with advanced or recurrent solid tumors [1][10]. - The first patient dosing represents a critical step in advancing Everest's proprietary mRNA technology platform into human trials, showcasing the company's commitment to innovative cancer treatments [5][6]. Group 2: Preclinical Studies and Efficacy - Preclinical studies have shown that EVM16 stimulates a strong neoantigen-specific T cell response and significantly inhibits tumor growth in mouse models [3][4]. - The combination of EVM16 with a PD-1 antibody has demonstrated synergistic anti-tumor effects, supporting its potential use in combination therapies [4][6]. - Safety and tolerability were confirmed in preclinical toxicity studies, indicating that repeated dosing of EVM16 is well tolerated [4][6]. Group 3: Market Context and Future Directions - According to Globocan data from 2022, there were approximately 19.976 million new cancer cases globally, highlighting the urgent need for innovative immunotherapies like personalized mRNA cancer vaccines [7]. - Everest Medicines is also developing a range of mRNA cancer therapeutics, including tumor-associated antigen vaccines and immunomodulatory cancer vaccines, with plans to submit investigational new drug applications in 2025 [8][11]. - The company aims to leverage its AI capabilities to enhance the precision of neoantigen recognition, positioning itself competitively in the biopharmaceutical industry [5][8].

Core Viewpoint - Everest Group reported a wider-than-expected operating loss in Q4 2024, driven by higher expenses and a decline in insurance performance, despite an increase in total operating revenues and net investment income [2][3][12]. Financial Performance - The operating loss for Q4 2024 was $18.39 per share, compared to a loss estimate of $16.65, and a significant drop from an operating income of $25.18 per share in the same quarter last year [2]. - Total operating revenues reached nearly $4.64 billion, marking a 26.7% year-over-year increase, surpassing the consensus estimate by 4.4% [3]. - Net investment income was $473 million, up 15.1% year over year, although it fell short of the Zacks Consensus Estimate of $496 million [4]. - Total claims and expenses surged 59% to $5.4 billion, primarily due to increased incurred losses and various underwriting expenses [5]. Segment Performance - The Reinsurance segment's gross written premiums increased by 12.6% year over year to $3.3 billion, driven by significant growth in Property Catastrophe XOL [7]. - The Insurance segment saw a decline in gross written premiums by 1.6% year over year to $1.3 billion, with notable growth in Property and Short Tail lines offset by decreases in Accident and Health and Specialty Casualty lines [8]. Financial Health - As of the end of Q4 2024, total investments and cash stood at $41.5 billion, an increase of 11.8% from the previous year, while shareholder equity rose by 5.1% to $13.9 billion [10]. - The book value per share was $322.97, reflecting a 6.1% increase from the end of 2023 [10]. - Cash flow from operations was reported at $4.9 billion, up 8.8% year over year, with common share dividends totaling $86 million for the quarter [11]. Full-Year Overview - For the full year 2024, operating income per share decreased by 55% year over year to $29.83, missing the Zacks Consensus Estimate by 23% [12]. - Total revenues for the year increased by 18.5% to $17.28 billion, slightly exceeding the consensus estimate by 1% [12]. Market Sentiment - Recent estimates for Everest Group have shown a downward trend, with a consensus estimate shift of -37.36% [13]. - The company currently holds a Zacks Rank of 5 (Strong Sell), indicating expectations of below-average returns in the coming months [15].

Core Insights - Everest Medicines, a biopharmaceutical company, is focused on discovering, developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines, particularly in the mRNA therapeutic vaccine space [1][6][7] Conference Call Details - The English session of the conference call is scheduled for 9:00 PM Beijing Time on March 6, 2025, which corresponds to 8:00 AM U.S. Eastern Time on the same day [2][3] - The Mandarin session will take place at 9:00 AM Beijing Time on March 7, 2025, equivalent to 8:00 PM U.S. Eastern Time on March 6 [4] - Access to the conference calls can be made through provided links and dial-in information for various regions, including the United States, Chinese Mainland, Hong Kong, and the United Kingdom [3][5] Company Overview - Everest Medicines aims to address critical unmet medical needs in Asian markets, with a management team that possesses extensive expertise from both global and local pharmaceutical companies [6][7] - The company has developed a portfolio of potentially global first-in-class or best-in-class molecules targeting renal diseases, infectious diseases, and autoimmune disorders [7]

Reinsurance Segment Performance - The Reinsurance segment wrote $12.9 billion of gross written premiums for the year ended December 31, 2024, with 90.5% ($11.7 billion) written through the broker reinsurance market[58]. - Property Pro Rata business accounted for 34.5% of reinsurance gross written premiums, while Casualty Pro Rata business accounted for 25.3%[59]. - The Reinsurance segment includes treaty and facultative reinsurance, with both types providing different coverage structures and risk-sharing arrangements[52]. - The Company competes with various international reinsurers and alternative risk providers, highlighting the dynamic nature of the market[62]. Insurance Segment Performance - The Insurance segment wrote $5.1 billion of gross written premiums in 2024, with various lines of business contributing to this total[65]. - The Insurance segment's Specialty Casualty business accounted for 28.1% of gross written premiums, while Professional Liability business accounted for 17.2%[67]. - The Insurance segment operates globally, with tailored products distributed through brokers and agents across multiple regions[64]. Financial Strength and Reserves - The financial strength ratings for the Company's operating subsidiaries are all rated A+ (Superior) by A.M. Best and A+ (Strong) by S&P[92]. - The Company believes that its existing reserves and reserving methodologies reduce the likelihood of material adverse effects on its financial condition[75]. - Reserves for unpaid property and casualty losses and LAE are established to cover future claims and related expenses, with potential material impacts on earnings if reserves are insufficient[71]. - As of December 31, 2024, the Company's gross reserves for Asbestos and Environmental (A&E) claims represented 0.9% of its total reserves[78]. Investment and Capital Management - The Company has expanded its investment portfolio to include fixed and floating rate securities, bank and private loan securities, private equity investments, and corporate-owned life insurance policies[87]. - The company has a statutory earned surplus of $8.1 billion as of December 31, 2024, which limits the amount of dividends it can pay without regulatory approval[110]. - The maximum amount available for dividend payments by Everest Re without triggering prior approval is $813 million as of December 31, 2024[110]. Regulatory and Compliance - The company is subject to periodic financial examinations every three to five years, with no material findings reported in 2024[134]. - The company maintains a minimum of $100 million in statutory capital and surplus as a Class 4 insurer in Bermuda[111]. - The company is licensed to write property and casualty insurance in all 50 states, the District of Columbia, Puerto Rico, and Guam[123]. - The company is authorized to conduct reinsurance business in Canada, Singapore, and Brazil, among other countries[124]. Risk Management - The Company’s Enterprise Risk Management (ERM) framework is integrated into daily operations and overseen by senior management risk committees[97]. - The Chief Risk Officer reports to the Board's Risk Management Committee, which evaluates the effectiveness of the ERM procedures and systems[102]. Taxation and Future Impacts - The Bermuda Corporate Income Tax Act 2023 will impose a 15% corporate income tax starting January 1, 2025, potentially affecting the company's deferred tax assets[141]. - The OECD guidance issued on January 15, 2025, may restrict the utilization of deferred tax benefits to approximately 20% of originally calculated amounts[141]. - The company does not expect the Inflation Reduction Act of 2022 to have a material impact on its results of operations[144]. - The company operates in multiple countries, including Australia, Belgium, Canada, and the U.K., where it is subject to local taxation[145]. Environmental Commitment - The company is committed to managing and reducing its ecological footprint while considering environmental factors in investment decisions[104].